Sanaz Ghafouri1, Aaron Burkenroad2, Morgan Pantuck3, Bara Almomani1, Dimitris Stefanoudakis4, John Shen1, Alexandra Drakaki5. 1. Division of Hematology and Oncology, David Geffen School of Medicine, UCLA, Los Angeles, USA. 2. Department of Medicine, David Geffen School of Medicine, UCLA, Los Angeles, USA. 3. Lewis Katz School of Medicine, Temple University, Philadelphia, USA. 4. University of Athens Medical School, Athens, Greece. 5. Division of Hematology and Oncology, David Geffen School of Medicine, UCLA, Los Angeles, USA. ADrakaki@mednet.ucla.edu.
Abstract
PURPOSE: To describe the role of anti-angiogenic agents that have been used as a treatment approach for locally advanced or metastatic urothelial cancers and to propose future directions. METHODS: PubMed/MEDLINE was searched for articles related to VEGF inhibition and locally advanced or metastatic urothelial cancer. RESULTS: Angiogenesis is a fundamental process for urothelial cancer initiation and progression. First-line therapy for locally advanced or metastatic urothelial cancer includes cisplatin-based chemotherapy combinations; subsequent systemic therapy includes taxanes, nanoparticle albumin-bound (nab) paclitaxel, or pemetrexed. More recently, several anti-PD-L1 and anti-PD-1 antibodies have shown promising activity in the first-line and post-platinum setting; however, immunotherapy remains ineffective in most patients. FGFR inhibitor erdafitinib was recently approved in the third-line setting. Studies on bevacizumab, pazopanib and ramucirumab have shown improved response rates when added to chemotherapy in selected patients, but have not led to overall survival (OS) benefit in randomized controlled studies. CONCLUSION: Anti-angiogenic agents have shown promise in recent studies treating locally advanced or metastatic urothelial cancer. However, further work is needed to elucidate ideal treatment combinations in selected patient populations to maximize benefit, with the ultimate goal of being added to the FDA-approved treatment armamentarium for this disease.
PURPOSE: To describe the role of anti-angiogenic agents that have been used as a treatment approach for locally advanced or metastatic urothelial cancers and to propose future directions. METHODS: PubMed/MEDLINE was searched for articles related to VEGF inhibition and locally advanced or metastatic urothelial cancer. RESULTS: Angiogenesis is a fundamental process for urothelial cancer initiation and progression. First-line therapy for locally advanced or metastatic urothelial cancer includes cisplatin-based chemotherapy combinations; subsequent systemic therapy includes taxanes, nanoparticle albumin-bound (nab) paclitaxel, or pemetrexed. More recently, several anti-PD-L1 and anti-PD-1 antibodies have shown promising activity in the first-line and post-platinum setting; however, immunotherapy remains ineffective in most patients. FGFR inhibitor erdafitinib was recently approved in the third-line setting. Studies on bevacizumab, pazopanib and ramucirumab have shown improved response rates when added to chemotherapy in selected patients, but have not led to overall survival (OS) benefit in randomized controlled studies. CONCLUSION: Anti-angiogenic agents have shown promise in recent studies treating locally advanced or metastatic urothelial cancer. However, further work is needed to elucidate ideal treatment combinations in selected patient populations to maximize benefit, with the ultimate goal of being added to the FDA-approved treatment armamentarium for this disease.
Authors: C N Sternberg; P H de Mulder; J H Schornagel; C Théodore; S D Fossa; A T van Oosterom; F Witjes; M Spina; C J van Groeningen; C de Balincourt; L Collette Journal: J Clin Oncol Date: 2001-05-15 Impact factor: 44.544
Authors: C N Sternberg; P de Mulder; J H Schornagel; C Theodore; S D Fossa; A T van Oosterom; J A Witjes; M Spina; C J van Groeningen; B Duclos; J T Roberts; C de Balincourt; L Collette Journal: Eur J Cancer Date: 2005-12-05 Impact factor: 9.162
Authors: H von der Maase; S W Hansen; J T Roberts; L Dogliotti; T Oliver; M J Moore; I Bodrogi; P Albers; A Knuth; C M Lippert; P Kerbrat; P Sanchez Rovira; P Wersall; S P Cleall; D F Roychowdhury; I Tomlin; C M Visseren-Grul; P F Conte Journal: J Clin Oncol Date: 2000-09 Impact factor: 44.544
Authors: Geolani W Dy; John L Gore; Mohammad H Forouzanfar; Mohsen Naghavi; Christina Fitzmaurice Journal: Eur Urol Date: 2016-10-28 Impact factor: 20.096
Authors: Yoo-Joung Ko; Christine M Canil; Som D Mukherjee; Eric Winquist; Christine Elser; Andrea Eisen; M Neil Reaume; Liying Zhang; Srikala S Sridhar Journal: Lancet Oncol Date: 2013-05-22 Impact factor: 41.316
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396